According to Benzinga Pro, GSK's peer group average for short interest as a percentage of float is 4.22%, which means the company has less short interest than most of its peers. Did you know that ...
Blujepa is the first new type of oral antibiotic to treat UTIs to gain approval in more than 20 years. Its development was ...
Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or ...
7d
Zacks Investment Research on MSNGSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
They don’t know what tariffs mean and they haven’t had them explained to them in ... Jim Cramer was recently asked about GSK plc (NYSE:GSK) in a latest program on CNBC. Here is what Cramer said in ...
13th Mar 2025 7:00 am RNS Transaction in Own Shares 12th Mar 2025 7:00 am RNS Transaction in Own Shares 11th Mar 2025 7:00 am RNS Transaction in Own Shares 10th Mar ...
GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February ...
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector ...
I’ll tell you what’s fetch: Tina Fey’s writing. With the original ‘Mean Girls’ film 20 years old, ‘30 Rock’ having wrapped up over a decade ago and even ‘The Unbreakable Kimmy ...
Mean nasal obstruction scores ... 83% (n=213) in the placebo group. Price Action: GSK stock is up 2.04% at $38.36 at the last check Monday.
GSK shared in back in October 2024 that depemokimab reduced nasal polyps in the ANCHOR trials, improving the total endoscopic nasal polyp score at 52 weeks as well as the mean nasal obstruction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results